In Brief: Gliatech Inc.
This article was originally published in The Gray Sheet
Gliatech Inc.: Reports results of two clinical studies demonstrating the clinical effectiveness of the firm's Adcon-L and Adcon-T/N resorbable, barrier gels in "inhibiting postoperative adhesions and improving surgical outcome." Presented the week of Aug. 18 at the International Society of Orthopedic and Trauma Surgeons World Congress in Amsterdam, one study of 267 first-time lumbar discetomy patients shows that Adcon-L "significantly decreased peridural scar and improved patient outcome by reducing the incidence of activity related pain while performing typical activities of daily living." In a study involving 32 hand tenolysis procedures, patients treated with Adcon-T/N "showed a 118% greater improvement in digital range of motion compared to controls." Gliatech has clinical trials ongoing in the U.S. for the two gel-based products...
You may also be interested in...
The company will use the proceeds to fund clinical trials, expand commercialization of its targeted radiation therapy, and file for CE marking in Europe.
Advanced Medical Solutions said it will buy Raleigh Adhesive Coatings for £22m ($29m) in cash to strengthen its overall wound care business.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.